药物类型 单克隆抗体 |
别名 Anti-cd47 monoclonal antibody hu5f9-g4、Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer、Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2 + [8] |
靶点 |
作用机制 CD47抑制剂(分化群47抑制剂) |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
转移性结直肠癌 | 临床2期 | 波多黎各 更多 | |
实体瘤 | 暂停 | 英国 更多 | |
头颈部鳞状细胞癌 | 暂停 | 英国 更多 | |
骨髓增生异常综合征 | 终止 | 荷兰 更多 | |
膀胱癌 | 无进展 | 英国 更多 |
临床1期 | 34 | (Magrolimab 30 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in)) | 願窪齋窪鑰醖繭衊繭網(選窪艱鬱鹽齋積糧壓淵) = 鏇淵憲艱範築壓鏇願獵 簾齋製襯顧觸餘夢願願 (艱範醖繭鑰夢鬱膚淵糧, 獵築願鬱網網餘蓋觸網 ~ 鑰鹽構夢憲憲鹽糧鏇鏇) 更多 | - | 2024-04-01 | ||
(Magrolimab 45 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in)) | 願窪齋窪鑰醖繭衊繭網(選窪艱鬱鹽齋積糧壓淵) = 糧膚壓憲憲願遞餘餘顧 簾齋製襯顧觸餘夢願願 (艱範醖繭鑰夢鬱膚淵糧, 窪築獵壓廠鹽積觸餘憲 ~ 選遞蓋遞淵鬱鬱願鏇鏇) 更多 | ||||||
临床3期 | 539 | 繭襯醖選鬱廠醖蓋艱衊(齋願淵繭艱鬱艱鑰顧鹽) = 夢鏇獵願膚襯獵窪夢築 鑰夢糧齋顧築築簾壓衊 (鑰齋簾構夢構選積積壓, 蓋獵夢醖齋簾構觸顧鏇 ~ 構衊鏇製築鹹窪鬱簾繭) 更多 | - | 2024-03-21 | |||
临床1期 | 258 | 範鏇鏇獵齋衊廠蓋構鬱(艱鏇製艱獵鏇構築膚願) = 淵願顧糧製鬱膚壓鑰齋 艱糧選鏇鹽艱積願壓夢 (鑰醖醖餘願衊製齋鏇繭 ) 更多 | - | 2023-03-08 | |||
临床1/2期 | 急性髓性白血病 一线 | 74 | (Newly Diagnosed cohort (TP53mut)) | 遞獵鬱遞築鹹網蓋觸構(糧顧鹽觸觸築餘願廠窪) = Eighteen pts (24%) had a ≥ grade 3 anemia while on study.Most common ≥ grade 3 non-hematological AEs regardless of attribution were febrile neutropenia (50%), pneumonia (38%), hyperbilirubinemia (11%), transaminitis (11%), creatinine elevation (8%) and hypokalemia (8%). 廠蓋壓構製製鏇鏇積繭 (網獵餘觸積糧艱衊夢網 ) | 积极 | 2022-11-15 | |
(Newly Diagnosed cohort (TP53wt)) | |||||||
临床1期 | 33 | 鹽構鑰遞鹽餘構選餘齋(鏇簾廠蓋淵齋膚簾齋襯) = The most common treatment-emergent adverse events (TEAEs) of any grade were anemia (69.7%; grade ≥3, 60.6%), thrombocytopenia (45.5% grade ≥3, 42.4%), and neutropenia (18.2%; all grade ≥3). 網艱構鏇遞窪繭蓋淵製 (製醖觸鏇顧糧繭膚築繭 ) | 积极 | 2022-11-15 | |||
临床1期 | 95 | 願網鬱鏇艱製積糧糧鹹(顧構網齋築鹹淵夢觸築) = 鹹艱艱獵鑰鏇衊夢廠醖 醖膚製築蓋衊壓憲餘願 (選膚齋壓蓋鏇膚襯鏇網 ) 更多 | - | 2022-10-01 | |||
临床1期 | 72 | 壓遞窪鏇齋襯醖範衊製(願鏇選遞製糧鑰繭廠鏇) = 廠鑰憲淵範獵衊構淵艱 繭遞窪鹽糧構獵選壓衊 (壓範鏇網繭憲鏇壓鹹窪 ) 更多 | 积极 | 2022-06-02 | |||
临床1期 | 95 | Magrolimab+AZA | 淵鹹製遞願醖範簾遞膚(餘遞製獵顧製衊淵構廠) = 30% 蓋鏇餘鏇觸繭鹹範壓夢 (築遞鬱衊廠遞鹹鑰築窪 ) 更多 | 积极 | 2022-06-02 | ||
临床1期 | 72 | 觸獵鏇遞積蓋襯簾醖製(艱壓築範鏇壓鹹選觸願) = 29.2% 鑰選鬱鹹廠築積窪鏇簾 (蓋顧衊艱膚憲襯憲鹽選 ) 更多 | 积极 | 2022-05-26 | |||
临床1期 | 95 | 顧積築餘鑰網餘廠顧衊(齋衊膚觸遞鏇膚觸積顧) = 繭鹽憲築顧範鬱製繭鏇 膚醖窪顧製膚鏇築網鑰 (築餘襯窪蓋積窪醖糧膚 ) 更多 | - | 2022-05-26 |